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Abstract  25 
The knowledge of sequences and structures of proteins produced by microbial pathogens is continuously 26 
increasing. Besides offering the possibility to unravel the mechanisms of pathogenesis at molecular level, 27 
structural information provides new tools for vaccine development, such as the opportunity to improve viral and 28 
bacterial vaccine candidates by rational design. Structure-based rational design of antigens can optimize the 29 
epitope repertoire in terms of accessibility, stability and variability. In the present study, we used epitope 30 
mapping information on the well characterized antigen of Neisseria meningitidis factor H binding protein (fHbp) 31 
to engineer its gonococcal homologue Ghfp. Meningococcal fHbp is typically classified in three distinct 32 
antigenic variants. We introduced epitopes of fHbp variant 1 onto the surface of the Ghfp, which is naturally able 33 
to protect against meningococcal strains expressing fHbp of variants 2 and 3. Heterologous epitopes were 34 
successfully transplanted, as engineered Ghfp induced functional antibodies against all three fHbp variants.  35 
These results confirm that structural vaccinology represents a successful strategy to modulate immune responses 36 





Neisseria meningitidis is still responsible for fatal disease worldwide (1). Glyco-conjugate vaccines against 40 
serogroups A,C,W,Y are available since early 2000s (2), while prevention of infection by meningococcus 41 
serogroup B (MenB) strains  has to be afforded to alternative antigens due to the poor immunogenicity of the 42 
serogroup B polysaccharide and  its structural similarity to human neural antigens, which raised concerns about 43 
the risk to induce auto-reactive antibodies (3). The research of novel candidates culminated with the 44 
development of two protein-based vaccines  approved for use in humans, one (Trumenba®) licensed in U.S. for 45 
use in individuals 10 through 25 years of age (4, 5), the second (Bexsero®) recommended in more than 30 46 
countries for all the age groups including infants  (6). Both vaccines contain factor H-binding protein (fHbp, 47 
alternatively named rLP2086 or GNA1870), a lipoprotein expressed by a large majority of circulating strains (7) 48 
and able to elicit a potent protective immune response against serogroup B (8-11). fHbp plays a fundamental role 49 
during the meningococcal infection, providing the bacterium with a way to evade the host serum surveillance. 50 
The protein, secreted across the outer membrane, is able to bind and sequester the human complement regulator 51 
factor H on the bacterial surface. This interaction prevents the activation of the alternative complement pathway 52 
and protects meningococci from killing (12, 13). 53 
fHbp shows a high level of genetic diversity. So far, more than 700 diverse fHbp peptide sequences are known, 54 
with amino acid identity ranging from about 62 to 99% (http://pubmlst.org/neisseria/fHbp/). On the basis of such 55 
variability, fHbp sequences have been classified as belonging to variant 1, 2 and 3 (8) or to sub-families A and B 56 
(9). Serological studies indicate that the genetic variability can have a profound influence in determining the 57 
ability of antibodies to kill fHbp-expressing strains, as  the immune response elicited by each variant ensures 58 
poor coverage against strains expressing heterologous alleles (8, 9). Inclusion of additional antigens (11) or 59 
combinations of distant fHbp sub-variants (9), are both strategies pursued to expand the vaccine coverage to 60 
virtually all circulating meningococcal strains. The fHbp sub-variant 1.1, included in the vaccine Bexsero® (11), 61 
represents the prototypic member of variant 1. In the past, we engineered this molecule in order to expand its 62 
coverage to variants 2 and 3. The resulting chimeric protein was able to protect mice against a panel of 63 
meningococcal strains expressing all the three variants (14). Recently, the gonococcal homologue of fHbp (Ghfp) 64 
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has been characterized by Jongerius et al. and proposed as an alternative broad-coverage vaccine candidate 65 
against meningococcal disease (15). Ghfp shows 60-94% of sequence identity to fHbp and demonstrated the 66 
ability to induce in mice antibodies able to kill natural meningococcal strains expressing different fHbp variants, 67 
although the effective response against variant 1 was relatively low and limited to the sub-variant 1.10. 68 
Moreover, Ghfp was unable to bind human factor H (15, 16), a desirable feature that can prevent partial masking 69 
of the protein surface to the immune system (15).  70 
In the present work we explored the possibility to increase the coverage of the immune response raised by Ghfp 71 
against meningococcal strains by inserting on its surface epitopes of fHbp sub-variant 1.1. 72 
The knowledge of the fHbp structure (17-20) provides the unique opportunity to deeply analyze distribution and 73 
accessibility of conserved and variant-specific residues. Moreover, a considerable ensemble of epitope mapping 74 
studies has been reported on fHbp. Pioneering mutagenesis studies identified critical residues for binding to 75 
bactericidal antibodies (21, 22). Subsequently, nuclear magnetic resonance (NMR) (23), hydrogen-deuterium 76 
exchange mass spectroscopy (HDX-MS) (24) and x-ray crystallographic studies (25) allowed remarkable 77 
progresses in mapping protective epitopes.  78 
The ensemble of this information makes members of the fHbp family ideal candidates for rational design studies 79 
attempting to modulate their immunogenicity by the introduction of heterologous epitopes from different 80 
variants.  81 
In order to introduce fHbp variant 1-specific epitopes onto Ghfp, we modified the gonococcal protein surface 82 
according to the information deriving from the NMR epitope mapping on fHbp. We previously mapped by NMR 83 
the epitope recognized by the monoclonal antibody MAb502 specific for fHbp sub-variant 1.1 (23). Here, we 84 
used the same approach to map the epitope of a second fHbp 1.1-specific monoclonal antibody called JAR 5 (26). 85 
Both MAb502 and JAR5 have been reported to induce a complement-mediated killing of meningococcal cells in 86 
presence of rabbit complement (22, 26). We decided therefore to introduce onto Ghfp both mAb502 and JAR5 87 
epitopes. Mice immunized with the resulting chimeric proteins elicited sera able to kill a wide panel 88 
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meningococcal strains belonging to variants 1, 2 and 3. This work represents an epitope mapping-based rational 89 
design that increased the antigenicity of Ghfp and it is in principle applicable to any vaccine candidate whose 90 
potential coverage is limited by sequence variability. 91 
Materials and methods 92 
Bacterial strains  93 
Escherichia coli DH5α and BL21 (DE3) were purchased from Invitrogen and used as cloning and expression 94 
strain, respectively. Ampicillin (Sigma) was used at concentration of 100 μg ml−1. 95 
Antibody generation 96 
The hybridoma cell line expressing JAR5 (26) was kindly provided by D. M. Granoff (CHORI). The murine 97 
IgG2b isotype monoclonal antibody JAR5 and the corresponding Fab fragment were produced and purified by 98 
Areta International SrL (Gerenzano, Italy).  99 
NMR sample preparation and interaction studies 100 
To express recombinant 2H/15N –labeled fHbp sub-variant 1.1 for NMR measurements, E. coli BL21(DE3) 101 
(pET21b-fHbp) was grown on M9 minimal medium in 80% 2H2O with the addition of glucose and 3.0 g of 102 
15NH4Cl (98% isotopic enrichment, Aldrich), as the sole carbon and nitrogen source, respectively. The culture 103 
was induced at A590 of 4.0 with 1.4 mM sterile filtered isopropyl 1-thio-β-D-galactopyranoside (Sigma) for 70 104 
min. The protein lacking the N-terminal leader peptide and the lipobox motif and containing a C-terminal 6x-His 105 
tag was purified by two chromatographic steps: Ni2+ affinity (His-Trap HP, 5-mL column; GE Healthcare), and 106 
cation exchange (HiTrap SP HP). Analytical gel filtration analysis showed that the recombinant protein was 107 
eluted as a monomer. The protein sample used for NMR experiments was subsequently dialyzed against 20mM 108 
sodium phosphate buffer at pH7.0. NMR samples contained 10% (v/v) 2H2O for NMR spectrometer lock.  109 
The interaction between the Fab fragment of JAR5 with 2H/15N-labeled fHbp sub-variant 1.1 was investigated 110 
with 1H–15N TROSY (Transverse Relaxation-optimized Spectroscopy)-HSQC experiments. All the NMR 111 
measurements were performed at 298 °K on a Bruker Avance 900 spectrometer, working at a 900.13-MHz 112 
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frequency and equipped with a cryogenically cooled probe. Titrations were performed on 0.4 mM 2H/15N –113 
labeled fHbp 1.1 protein samples with the unlabeled JAR5 up to an fHbp–JAR5 molar ratio of 1:1.5. 1H and 15N 114 
resonance assignments for the fHbp sub-variant 1.1 protein were already available (27). 115 
Cloning and expression of Ghfp mutants 116 
The DNA sequence of N. gonorrhoeae strain FA1090 ghfp devoid of the region encoding the leader peptide and 117 
the N-terminal glycine stretch was used as starting point to generate the three chimeric proteins. The amino acid 118 
substitutions were introduced avoiding the use of rare codons for arginine. The 3 synthetic genes were purchased 119 
from GeneArt (Invitrogen) to include NdeI and XhoI restriction sites at the 5′ and 3′ ends, respectively. Each 120 
gene was digested with NdeI/ XhoI and cloned into the corresponding sites of the pET21b(+) vector (Novagen). 121 
The expression vectors were transformed into E. coli BL21 (DE3). The recombinant cells were grown at 37°C to 122 
an optical density at 600 nm of ∼0.5, at which time 1 mM isopropyl-beta-D-thiogalactopyranoside (IPTG) was 123 
added and the cultures were allowed to grow for 3 hours. Cells were harvested by centrifugation at 4000 rpm for 124 
15 min at 4°C.  125 
Protein Purification  126 
Bacterial pellets were re-suspended in 10 ml of Buffer A IMAC (50 mM NaH2PO4 [Sigma], 300 mM NaCl 127 
[Fluka], 30 mM imidazole [Merck]; pH 8.0), sonicated and then centrifuged at 35,000 × g for 30 min. The 128 
supernatant was collected and subjected to two serial purification steps using metal affinity chromatography 129 
(IMAC) and ionic exchange chromatography with a desalting step in between. All purification steps were 130 
performed using an AKTAXpress chromatographic system, and the OD280 was monitored. For the IMAC 131 
purification step, filtered supernatants were automatically injected into 1-ml Ni2+-HisTrap HP columns with a 132 
flow rate of 1 ml/min, and columns were washed with 20 column volumes (CV) of washing buffer (50 mM 133 
NaH2PO4 [Sigma], 300 mM NaCl [Fluka], 30 mM imidazole [Merck]; pH 8.0). Then, the His tag fusion proteins 134 
were eluted with 5 CV of elution buffer (50 mM NaH2PO4, 300 mM NaCl, 500 mM imidazole; pH 8.0), and 135 
automatically loaded on three 5-ml HiTrap (GE) desalting columns connected in series and eluted with a flow 136 
rate of 5 ml/min in 50 mM Tris-HCl pH8.0. For ionic exchange chromatography, the eluted proteins were 137 
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automatically loaded on 1-ml HiTrap Q HP columns with a flow rate of 1 ml/min. Subsequently, the column was 138 
washed with 10 CV of 50 mM Tris-HCl, pH 8.0. The elution was set up in a linear gradient, between 50 mM 139 
Tris-HCl (pH 8.0) and 50 mM Tris-HCl, 1.0 M NaCl (pH 8.0) buffer in 10 CV, and 1-ml fractions were 140 
collected. Protein purity resulted more than 95% for all the samples, as by densitometry analyses of SDS-Page 141 
12% gel. Protein aggregation and apparent Molecular weight were checked by analytical size-exclusion 142 
chromatography (Waters Acquity UPLC system equipped with BEH200 1.7 mm column 4,6x300mm (waters), 143 
150 mM NaP buffer pH 7.0 at a flow rate of 0.4 ml/min). All the protein samples resulted more that 95% in the 144 
monomeric form. A table summarizing the features of the purified recombinant proteins is reported as Table S1 145 
in Supplementary Material. 146 
Surface Plasmon Resonance (SPR) analysis  147 
 SPR was used to analyze the binding of fHbp and chimeric proteins to MAb502 and JAR5. All SPR 148 
experiments were performed using a Biacore T200 instrument at 25 °C (GE Healthcare). In brief a 149 
carboxymethylated dextran sensor chip (CM-5; GE Healthcare) was prepared where high densities (∼10,000 150 
response units (RUs)) of anti-mouse antibodies from a commercially available Mouse Antibody Capture Kit (GE 151 
Healthcare) were immobilized by amine coupling. The anti-mouse IgG chip was used then to capture ~1000-152 
1500RU of MAb 502 and JAR5. Proteins, purified as described before, and diluted in buffer contained 10 mM 153 
Hepes, 150 mM NaCl, 3 mM EDTA, 0.05% (vol/vol) P20 surfactant, pH 7.4 (HBS-EP), to a final concentration 154 
of 200 nM for the single injection experiments and to a range of five consecutive injections of increasing analyte 155 
concentration (2.5 nM to 40 nM) for the Single Cycle Kinetics (SCK) experiments (28) were injected over the 156 
captured antibodies. Surfaces were then regenerated with 10 mM glycine pH 1.7. Anti-mouse antibody-coated 157 
surfaces without captured monoclonal antibody were used as the reference channel. A blank injection of buffer 158 
only was subtracted from each curve, and reference sensorgrams were subtracted from experimental sensorgrams 159 
to yield curves representing specific binding. The data shown are representative of at least two independent 160 
experiments. SPR data were analyzed using the Biacore T200 Evaluation software (GE Healthcare).  For the 161 
SCK experiments each sensorgram was fitted with the 1:1 Langmuir binding model, including a term to account 162 
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for potential mass transfer, to obtain the individual kon and koff kinetic constants; the individual values were then 163 
combined to derive the single averaged KD values reported.  164 
 Binding to human factor H was also analyzed in two experimental setups. First, purified full length factor H 165 
(Calbiochem) was covalently immobilized by amine coupling on a CM5 chip to reach a density of ∼2500 RU. 166 
Proteins at a concentration of 200nM in PBS were injected and binding levels were compared. Regeneration 167 
between injections was achieved by a single injection of 10mM Glycine pH 3, 3M NaCl solution. In order to 168 
assess the effect of several factor H concentrations on the binding, proteins were covalently immobilized by 169 
amine coupling on a CM5 chip on different flow cells to reach a density of ∼300-400 RU. Full length factor H 170 
was then injected at increasing concentrations (0.07-2μM) and binding to the different surfaces was compared. 171 
Following each injection, sensor chip surfaces were regenerated with a 30-second injection of 50mM NaOH. 172 
Differential Scanning Calorimetry (DSC) 173 
Thermal stability of the mutants was checked by DSC experiments performed with a MicroCal VP-Capillary 174 
instrument (GE Healthcare) with integrated auto-sampler. Samples were dialyzed in PBS to a final protein 175 
concentration of 0.5 mg/ml. DSC scans were recorded in the temperature range of 10-110°C with a thermal 176 
ramping of 200°C per hour and a 4 second filter period. Data were analyzed by subtraction of the reference data 177 
for a sample containing only buffer, using the Origin 7 software (OriginLab). 178 
Antigen formulation 179 
All formulations were performed in sterile conditions under a flow hood. Each recombinant protein was 180 
adsorbed onto aluminum hydroxide at protein, aluminum (alum), and NaCl concentrations of 100 μg/ml, 3 181 
mg/ml, and 9 mg/ml, respectively, in 10 mM histidine (pH 6.5). Water for injection and histidine buffer were 182 
premixed. Sodium chloride was added to result in a final formulation osmolality of 0.300 mosmol/kg. Alum 183 
addition was calculated on the basis of the concentration of the alum stock to obtain a final concentration of 3 184 
mg/ml. Antigens at respective concentrations were added to the mix and left for 15 min under stirring at room 185 
temperature and then stored overnight at 4°C before the immunization. Final formulations were isotonic and at 186 
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physiological pH. All alum formulations were characterized soon after immunization, antigen adsorption 187 
was >90%, and adsorption profile was similar for all antigens and adjuvants tested. 188 
Bactericidal activity assay 189 
To prepare antisera, 20 μg of protein were used to immunize 6-week-old CD1 female mice (Charles River). 190 
Eight mice per group were used. The antigens were administered intra-peritoneally (i.p.), together with 191 
aluminum hydroxide (3 mg/ml), on days 0, 21, and 35. Two weeks after the third immunization, the sera were 192 
collected and pooled. Serum bactericidal antibody activity of mice immune sera was evaluated as previously 193 
described by Borrow et al (29) against the N. meningitidis strains listed in Table 1.  Pooled baby rabbit serum 194 
was used as the complement source. Bactericidal titers in presence of rabbit complement (rSBA) were expressed 195 
as the reciprocal of the final serum dilution step giving ≥50% killing at 60 min compared to the number of CFU 196 
at time zero. 197 
Fluorescence-Activated Cell Sorter (FACS) analysis of fHbp expression 198 
The ability by mouse polyclonal anti-fHbp sera to bind the surface of meningococci was measured using a 1:100 199 
dilution of mouse polyclonal antiserum raised by the same fHbp variant when available, or by closely related 200 
alleles (25). Primary antibody binding was detected by using an anti-mouse (whole-molecule) FITC-conjugated 201 
antibody (Sigma) at a 1:100 dilution. 202 
Results 203 
NMR epitope mapping   204 
fHbp 1.1 is one of the protein sub-variants more frequently found during epidemiological surveys worldwide (30, 205 
31). For this reason, several studies have been reported describing the epitopes of this protein recognized by 206 
bactericidal monoclonal antibodies. In a previous study, we mapped the fHbp site recognized by MAb502 in one 207 
of edges of the carboxyl-terminal beta barrel domain (23). Previous mutagenesis work reported by Beernink et al. 208 
indicated that JAR5 targets the N-terminal domain of fHbp, in a region overlapping the binding site to factor H 209 
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(21). Such preliminary evidences suggested that MAb502 and JAR5 recognized well distinct regions of the fHbp 210 
surface and were able to cooperate in inducing a protective immune response against fHbp sub-variant 1.1 (21).  211 
To identify the residues forming the JAR5 epitope we applied the same NMR-based approach that we previously 212 
used to map MAb502 (23). Briefly, 1H, 15N HSQC NMR spectra were acquired on 2H/15N –labeled fHbp in 213 
presence and absence of the JAR5 Fab fragment. Changes in the chemical environment caused by Fab binding 214 
were expected to change the chemical shift of backbone NH groups. Residues of fHbp experiencing chemical 215 
shift changes upon the addition of JAR5 are listed in Table S2. With the exception of Gln38, Ser39 and Asn43, 216 
all the affected residues were localized on four adjacent beta strands of the N-terminal domain (Fig.1A).  Gln38, 217 
Ser39 and Asn43 were not considered as a part of the JAR5 epitope, due to the distance from all the other 218 
perturbed residues. Remarkably, the epitope defined by NMR includes both Gly121 and Lys122, previously 219 
identified by Beernink and colleagues as essential for binding to JAR5 (21). 220 
The ensemble of perturbed residues formed a solvent accessible surface of 2860 Å2, a value exceeding the range 221 
of 900-2000 Å2 typical of conformational epitopes characterized so far (32-34). We cannot however exclude that 222 
some perturbation effects could be ascribed to local conformational rearrangements occurring after the 223 
interaction with the antibody rather than direct contact with JAR5, leading to an over-estimation of the epitope 224 
extension. 225 
No overlap was observed between JAR5 and MAb502 epitopes (Table S2 and Fig.1B) while, in line with the 226 
observation that JAR5 can inhibit the fHbp interaction with factor H (21), JAR5 epitope resulted largely 227 
overlapping to the factor H binding site (Table S2) 228 
Design of chimeric Ghfps 229 
The aim of this work was to design a broad coverage antigen against Neisseria meningitidis by engineering the 230 
Ghfp surface. We selected as a scaffold the Ghfp from Neisseria gonorrhoeae strain FA1090, which encodes a 231 
fHbp homologue unable to bind human factor H and closely related to members of fHbp variant 3 (Fig.2). The 232 
substitution of some surface-accessible residues of Ghfp with amino acids specifically present in fHbp variant 1 233 
was expected to result in the creation of a chimeric molecule containing epitopes of both variants. Extension and 234 
11 
 
localization of the fHbp sub-variant 1.1 epitopes recognized by MAb502 and JAR5 were used to identify the 235 
portions of the Ghfp surface to be modified.   236 
In order to produce chimeric proteins able to elicit antibodies cross-protective across all sub-variants 1, we 237 
aligned the amino acid sequences of fHbp 1.1. to 1.3, 1.14 and 1.15, the most divergent sub-variants among the 238 
highly common isolates belonging to variant 1 (30) (Fig.S3). Then, selected groups of concurrent substitutions 239 
deduced from the multiple sequence alignment were introduced in each chimeric protein. In Fig.3 the amino acid 240 
sequences of the wild-type gonococcal scaffold and the meningococcal allele MC58 used to elicit in mice both 241 
JAR5 and MAb502 are compared to the mutants. Overall, 29, 30 and 31 amino acid substitutions were made on 242 
FA1090 to generate NG_5.2, NG_5.6 and NG_5.8 respectively. The resulting three mutants, as well as Ghfp and 243 
the fHbp sub-variants 1.1 and 3.28 were expressed in E. coli as hexa-histidine-tagged proteins. 244 
The effects of the substitutions on thermal stability of the proteins were investigated by DSC. In DSC 245 
experiments a melting temperature (Tm) value is given by the peak maximum in the scanned curve. Differently 246 
from the meningococcal fHbp, typically showing two very well distinct transitions (Tm1 at 70°C and Tm2 at 80-247 
90°C), corresponding to N- and C-terminal domains respectively (17), the thermal unfolding of Ghfp appeared to 248 
be much more cooperative. The DSC profile of the gonococcal protein could be de-convoluted in two nearly 249 
overlapping peaks with very similar melting temperatures (Tm1 at 58°C and Tm2 at 67°C) and a sensibly low 250 
enthalpy in the case of the second transition (Fig.4A).  251 
All the mutants showed values of Tm1 similar to the gonococcal wild type, while Tm2 sensibly increased in 252 
NG_5.2 and NG_5.6, reaching values more in line with those observed for the C-terminal domain of 253 
meningococcal fHbp (Fig.4B). We concluded therefore that mutations introduce to mimic the MAb502 epitope 254 
stabilized the C-terminal domain of NG_5.2 and NG_5.6, while the JAR5-related mutations left the N-terminal 255 
domain substantially unaffected.  256 
Functional analysis of the mutants 257 
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The interaction of each mutant with the full length human factor H was tested by SPR, in order to evaluate 258 
whether substitutions had any impact on such interaction. Differently from the strong concentration-dependent 259 
interaction observed between fHbp variant 1.1. and human fH, no binding was detectable in the case of Ghfp and 260 
all the immobilized mutants to increasing concentrations of human factor H up to 2μM (Fig.5). These results led 261 
to exclude that any residue necessary to re-establish the interaction was introduced by the JAR5 epitope grafting. 262 
In order to check the ability by the mutants to properly present the MAb502 and JAR5 epitopes, the interaction 263 
with each monoclonal antibody was also investigated by SPR (Table 2 and Fig. 6). As expected, substitutions 264 
introduced in NG_5.2 conferred to the molecule the ability to bind MAb502 with affinity comparable to fHbp 265 
sub-variant 1.1. Binding to MAb502 was instead compromised in NG_5.6 and NG_5.8.  In both these mutants 266 
the gonococcal serine 204 was replaced by histidine (Fig. 3), the residue naturally occurring in sub-variants 1.14 267 
and 1.15 (Fig. S3). We hypothesize that the absence of arginine 204, previously identified as critical for the 268 
interaction of fHbp sub-variant 1.1 with MAb502 (22), prevented the binding to NG_5.6 and NG_5.8.  269 
All the three mutants were able to bind JAR5 with comparable affinity, although only NG_5.2 showed the slow 270 
dissociation rate characteristic of fHbp sub-variant 1.1. 271 
Overall the SPR analysis provided a preliminary indication that surface regions corresponding to MAb502 and 272 
JAR5 epitopes were successfully introduced on the gonococcal protein and sufficiently well exposed on the 273 
protein surface to be recognized by respective monoclonal antibodies. 274 
The immunogenicity of NG_5.2, NG_5.6 and NG_5.8 was then evaluated by a serum bactericidal assay (SBA) 275 
on the strains reported in Table 1. To confirm the fHbp accessibility to antibodies, we first probed the 276 
meningococcal strains by FACS (Fig. 7). Mouse polyclonal sera elicited by homologous or closely related fHbp 277 
sub-variants were used to detect fHbp on the bacterial surface. FACS profiles revealed that fHbp was well 278 
accessible to antibodies in all the strains tested. Moreover, strains with higher (MC58, M01-02400660, M08-279 
02400104), intermediate (M12566, M01-0240988, M01-02400355,) or lower (M14879, NZ98/254, M1239, 280 
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LNP024551) fHbp accessibility could be distinguished, suggesting that sequence diversity and protein exposure 281 
could both have influence on the bactericidal titers. 282 
Groups of eight mice were immunized with NG_5.2, NG_5.6 or NG_5.8. Controls included animals vaccinated 283 
with Ghfp, fHbp sub-variants 1.1 and 3.28. The ability of the chimeric proteins to elicit functional antibodies 284 
was evaluated by measuring the complement-mediated killing induced by the immune sera in vitro. Values of 285 
rSBA <16 were considered negative as this is the starting dilution for the experiments.  286 
A summary of the rSBA analysis is reported in Table 3. Ghfp induced a bactericidal immune response against 287 
meningococcal strains expressing fHbp variants 2 and 3 but failed to protect mice against variant 1. Conversely, 288 
bactericidal activity against variant 1 was observed, at different levels, after vaccination with each of the three 289 
mutants. Complement mediated killing of all the variant 1 isolates was induced by sera of mice immunized with 290 
NG_5.6 and NG_5.8. Despite that fact that NG_5.2 was the only mutant able to bind MAb502 (Fig. 5B), the 291 
NG_5.2 immune sera exhibited moderate bactericidal titers all the variant 1 strains. The loss of bactericidal 292 
activity against NZ98/254 and the low titer against M14879 could be due to the limited amount of fHbp detected 293 
on their surface (Figure 7). To explain the relatively low titers observed against MC58 we speculated that few 294 
mismatches of surface-exposed residues like aspartate 163 (glycine in MC58) and histidine 178 (asparagine in 295 
MC58) (Fig.3) might have counteracted the positive effects of the epitope grafting. Alternatively, changes in the 296 
conformational equilibrium induced by the NG_5.2-specific substitutions (Fig.4) could have indirectly 297 
influenced the variant 1 epitope presentation.  298 
NG_5.6 and NG_5.8 retained also the ability to kill all the strains of variant 2 and variant 3, although a sensible 299 
decrease in bactericidal activity compared to the gonococcal wild type was observed, particularly against the low 300 
fHbp expressing strains of variant 3 M1239 and LNP24551. Bactericidal titers against variants 2 strains were 301 
also elicited by NG_5.2. This mutant resulted unable to promote the complement-mediated killing against 302 







Molecular grafting of functional epitopes is a promising way to improve variable antigens or realize novel 308 
proteins with pre-specified functionalities. Side chain and backbone remodeling have been recently proposed as 309 
protein design strategies to stabilize and optimize protein antigens for presentation of contiguous conformational 310 
epitopes (35-37).  311 
In a previous study, we engineered the C-terminal domain of fHbp 1.1 by introducing residues specific of 312 
variants 2 and 3 within patches of about 1000 A2 (14). The mutagenesis was applied to the entire immuno-313 
dominant carboxyl-terminal domain of the protein, whose surface was systematically explored in order to 314 
identify the region(s) able to well tolerate the epitope grafting in terms of folding and immunogenicity. In the 315 
present work we decided to explore the possibility to modulate the immunogenicity of the gonococcal fHbp 316 
orthologue Ghfp by selectively grafting pre-defined meningococcal epitopes from the distantly related fHbp sub-317 
variant 1.1.  318 
A deep structural knowledge of sub-variant 1.1-specific protective epitopes allowed limiting the mutagenesis on 319 
the regions of protein surface specifically recognized by anti-sub-variant 1.1 antibodies. We previously reported 320 
the characterization by NMR of the epitope recognized by the murine monoclonal antibody MAb502. The 321 
antibody binding site covered a surface of 1992 A2 entirely located on one apex of the carboxyl-terminal domain 322 
of the protein and distant from the site of interaction with factor H (23). In the present study, we mapped the 323 
epitope of a second monoclonal antibody, JAR5, previously reported to target Gly121 and Lys122 on fHbp sub-324 
variant 1.1 and able to inhibit the binding to factor H (21). Such observations suggested that the region 325 
recognized by JAR5 was well distinct from the MAb502 epitope. The present results confirmed this prediction. 326 
The JAR5 epitope identified by NMR resulted entirely located within the N-terminal domain of fHbp excluding 327 
any overlap with the region recognized by MAb502. Remarkably, the JAR5 epitope resulted localized in the 328 
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same region where the epitopes of two murine IgG1 monoclonal antibodies (17C1 and 30G4) were previously 329 
mapped by hydrogen-deuterium exchange mass spectrometry (24). Both 17C1 and 30G4 displayed, although to 330 
different extents, synergistic bactericidal activity against strains of variant 1 when used in combination with 331 
MAb502. These results suggested that co-transplantation of the JAR5 and MAb502 epitopes in a fHbp variant 3-332 
like environment could potentially result in a molecule able to induce a potent protective immunity against 333 
variant 1 strains.  334 
Serum bactericidal activity assay measures the ability of immune sera to mediate killing of meningococci in vitro, 335 
in presence of an exogenous source of complement. In a previous study, Jongerius and colleagues evaluated the 336 
ability by Ghfp to induce bactericidal antibodies against meningococcal strains expressing variants 1, 2 or 3 (15). 337 
They tested a panel of seven isolates and observed comparable bactericidal activity across the three variants. A 338 
remarkable exception was represented by MC58 strain (fHbp sub-variant 1.1), which was resistant to killing by 339 
anti-Ghfp antibodies.  In the present work, we analyzed a different set of meningococcal isolates, which included 340 
four strains expressing different sub-variants 1. All the fHbp variant 1-expressing isolates tested were not killed 341 
by anti-Ghfp serum according to the observation that molecules of variant 3 do not induce bactericidal antibodies 342 
against variant 1 (8, 38).  343 
Ghfp induced bactericidal antibodies against M12566 and M1239, expressing fHbp 2.19 and 3.28 sub-variants 344 
respectively, with SBA titers comparable to those reported by Jongerius et al. for the same sub-variants (15). 345 
M08-240104 and M01-240355 strains, expressing fHbp 2.16 and 3.4 sub-variants respectively, showed a more 346 
pronounced sensitivity to the bactericidal activity of the anti-Ghfp immune sera. In the case of M01-240355 this 347 
could be due to the highest sequence similarity to Ghfp of the fHbp 3.4 sub-variant (93.51 % of identity at amino 348 
acid level) compared to all the other meningococcal strains of the panel (Table S3). The M08-240104 sequence 349 
87% identical to Ghfp cannot be however invoked to explain the high sensitivity of this strain to the Ghfp 350 
immune serum. It is possible that the high fHbp expression level, together with the conservation of a small 351 
number of specific residues residing within crucial epitopes, render M08-240104 more susceptible to killing by 352 
anti-Ghfp antibodies.  353 
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Overall, the results of the bactericidal activity assay showed that the mutagenesis was able to introduce a local 354 
molecular mimicry of fHbp variant 1 sufficient to elicit antibodies bactericidal against a panel of natural 355 
meningococcal strains expressing different sub-variants. In particular, NG5.6 and NG5.8 were both able to elicit 356 
a protective immune response  against all variant 1 strains tested, included isolates expressing some of the most 357 
prevalent alleles like 1.1 and 1.13 (7).  358 
A general decrease of bactericidal titers against variant 3 was observed in sera elicited by the mutants compared 359 
to those obtained by the immunization with the wild type gonococcal protein. The total area including MAb502 360 
and JAR5 epitopes accounts for about 13% of the fHbp surface and both epitopes resulted localized on the 361 
predicted accessible side of the molecule. The changes introduced in the gonococcal protein reduced the surface 362 
area available to elicit variants 3 specific antibodies. This could has been particular critical in the case of variant 363 
3 strains, were fHbp expression levels were generally lower compared to variant 1. Alternatively, the 364 
modifications could have specifically altered epitopes critical for variant 3. Finally, we cannot exclude that 365 
modifications in the amino acid sequence could have introduced some local conformational change of the 366 
molecule that altered the original epitope repertoire. The DSC profile of the mutants indicated that substitutions 367 
increased the thermal stability of the proteins, presumably stabilizing the overall fold. However, how this could 368 
reflect changes in the immunogenicity remains unclear.  369 
In conclusion, we enhanced the potential of Ghfp as a vaccine candidate by threading in defined portions of its 370 
surface two well characterized heterologous functional epitopes.  Although a clear correlation between the 371 
bactericidal titers obtained in mice with rabbit complement and bactericidal response in humans has not been yet 372 
defined, the positive titers reported in the present study indicate that the chimeric proteins have the potential to 373 
raise protective immunity against a wider panel of meningococcal strains compared to native Ghfp.  The detailed 374 
epitope characterization obtained by NMR provided valuable information for antigen optimization, permitting to 375 
limit the mutagenesis within restricted regions of the protein surface and minimize the changes of naturally 376 
occurring sequences. This aspect assumes particular relevance for the optimization of large proteins where 377 
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Figure Legends 387 
Figure 1 A - NMR mapping of the epitopes recognized by JAR5 and MAb502. Residues involved in the 388 
interaction with JAR5 are depicted in green (A). The epitope of mAb502 is colored in red and reported in panel 389 
B according to Ref. (23).  390 
Figure 2 - Classification tree of the different fHbp alleles used in this study. Ranges of amino acid sequence 391 
identity of fHbp variants 1, 2 and 3 to Ghfp are reported in brackets.  Multiple sequence alignment has been 392 
carried out with ClustalW (39) available at NPS@ server. Dendrogram was obtained at Phylogeny.fr server with 393 
TreeDyn (40). 394 
Figure 3 - Multiple sequence alignment of the engineered proteins (NG_5.2, NG_5.6 and NG_5.8)  to the wild 395 
type Ghfp and the fHbp sub-variant 1.1. The asterisk marks positions 163, 178 and 204, critical for mAb502 396 
binding to fHbp sub-variant 1.1. 397 
Figure 4 - DSC analysis of engineered Ghfp proteins. The overlapping peaks in the melting curve of Ghfp (Panel 398 
A, grey line) have been calculated by applying a non-2 state fitting model according to the Levenberg-Marquardt 399 
non-linear least-square method using Origin 7 software. All the mutants generated two well distinct peaks (Panel 400 
B), consistent with two unfolding events.  401 
Figure 5 - Interaction of immobilized engineered proteins with factor H analyzed by SPR. BIAcore sensorgrams 402 
show the dose dependent response over time (resonance units [RU]) during the binding of increasing 403 
concentrations of factor H (up to 2μM) on immobilized recombinant fHbp while no binding is observed with the 404 
immobilized Ghbp proteins. 405 
Figure 6 - Interaction of engineered Ghfp proteins with JAR5 (A) and mAb502 (B) analyzed by SPR. 406 
Representative BIAcore sensorgrams show the response over time (resonance units [RU]) during the binding of 407 
purified recombinant proteins to immobilized mAbs.   408 
Figure 7 - FACS analysis of fHbp surface expression and factor H binding of N. meningitidis strains used in this 409 
study. The presence of fHbp on the meningococcal cell surface was detected by binding of mice polyclonal sera 410 
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elicited the same fHbp sub-variant when available, or by closely related alleles. In each panel, amino acid 411 
identity between fHbp used to immunized mice and the genetic variant expressed by the strain tested is reported 412 
in brackets.  Shaded and white profiles show reaction with pre-immune and immune serum, respectively.   413 
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Strain Clonal complex ST Year Country Serogroup:serotype:serosubtype fHbp sub-
variant 
MC58 32 74 1985 UK B:15:P1.7,16b 1.1 
M14879 1157 1157 2006 USA B:NA:P1.22,14-6 1.13 
NZ98/254 41/44 42 1998 NZ B:4:P1.4 1.14 
M01-0240660 269 269 2001 UK B:NA:P1.19,15 1.15 
M08-240104 35 35 2008 UK B:4:P1.14 2.16 
M12566 41/44 5111 2004 USA B:4,7:P1.4 2.19 
M1239 41/44 437 1995 USA B:14:P1.23, 14 3.28 
M01-240988 213 213 2001 UK B:1:NA 3.30 
M01-240355 213 213 2001 UK B:1:NA 3.31 
LNP24551 32 34 2008 FR B:4:P1.5,2 3.116 
 559 
Table 1 – Meningococcal strains used in this study. The fHbps are named in terms of the translated (protein) 560 
sequence, as variant class.protein ID, in accordance with the public fHbp database 561 
(http://pubmlst.org/neisseria/fHbp/), in which new protein variants are assigned a sequential numerical identifier, 562 
alongside a prefix corresponding to the Novartis variant designation (variant 1, 2, or 3). For example, fHbp 1.1 563 
refers to Novartis sub-variant 1, neisseria.org protein subvariant 1. ST, sequence type as determined by MLST; 564 















mAb protein kon (M-1 s-1) koff (s-1) KD (M) 
MAb502 fHbp  1,93 E+06 0.84 E-02 4.34 ± 0.03 E-09 
MAb502 NG 5.2 0.63 E+06 2.85 E-03 4.53 ± 0.01 E-09 
JAR5 fHbp  0.81 E+06 2.15 E-04 2.63 ± 0.001 E-10 
JAR5 NG 5.2 0.58 E+06 2.15 E-04 3.71 ± 0.02 E-10 
JAR5 NG 5.6 0.82 E+06 3.71 E-03 4.53 ± 0.09 E-09 
JAR5 NG 5.8 0.88 E+06 3.86 E-03 4.39 ± 0.15 E-09 
 578 
Table 2. Summary table of SCK experiments of the monoclonal antibodies binding to the Ghfp proteins with kon, 579 





rSBA   
    antigen   
STRAIN fHbp variant NG5.6 NG5.8 NG5.2 NGFA1090 fHbp 3.28 (M1239) 
fHbp 1.1 
(MC58) 
MC58 v1.1 512 128 256 <16 <16 >8192* 
M14879 v1.13 1024 1024 64 <16 <16 1024 
NZ98/254 v1.14 256 512 <16 <16 <16 128* 
M01-240660 v1.15 4096 4096 512 <16 <16 2048 
M08-240104 v2.16 2048 128 256 >8192 2048 16 
M12566 v2.19 128 128 1024 512 256 <16 
M1239 v3.28 64 16 <16 256 2048 <16* 
M01-240988 v3.30 512 128 32 512 32 <16 
M01-240355 v3.31 256 256 128 2048 512 <16 
LNP24551 v3.116 64 64 <16 512 <16 <16 
 583 
Table 3 - Serum bactericidal titers elicited in mice by engineered antigens against the panel of strains described 584 
in Table 1. Wild type Ghfp, as well as fHbp sub-variant 1.1 and 3.28 have been also included as control. 585 









Strain Clonal complex ST Year Country Serogroup:serotype:serosubtype fHbp sub-
variant 
MC58 32 74 1985 UK B:15:P1.7,16b 1.1 
M14879 1157 1157 2006 USA B:NA:P1.22,14-6 1.13 
NZ98/254 41/44 42 1998 NZ B:4:P1.4 1.14 
M01-0240660 269 269 2001 UK B:NA:P1.19,15 1.15 
M08-240104 35 35 2008 UK B:4:P1.14 2.16 
M12566 41/44 5111 2004 USA B:4,7:P1.4 2.19 
M1239 41/44 437 1995 USA B:14:P1.23, 14 3.28 
M01-240988 213 213 2001 UK B:1:NA 3.30 
M01-240355 213 213 2001 UK B:1:NA 3.31 
LNP24551 32 34 2008 FR B:4:P1.5,2 3.116 
 
mAb protein kon (M-1 s-1) koff (s-1) KD (M) 
MAb502 fHbp  1,93 E+06 0.84 E-02 4.34 ± 0.03 E-09 
MAb502 NG_5.2 0.63 E+06 2.85 E-03 4.53 ± 0.01 E-09 
JAR5 fHbp  0.81 E+06 2.15 E-04 2.63 ± 0.001 E-10 
JAR5 NG_5.2 0.58 E+06 2.15 E-04 3.71 ± 0.02 E-10 
JAR5 NG_5.6 0.82 E+06 3.71 E-03 4.53 ± 0.09 E-09 
JAR5 NG_5.8 0.88 E+06 3.86 E-03 4.39 ± 0.15 E-09 
 
rSBA   
    antigen   
STRAIN fHbp variant NG_5.6 NG_5.8 NG_5.2 Ghfp fHbp 3.28 (M1239) 
fHbp 1.1 
(MC58) 
MC58 v1.1 512 128 256 <16 <16 >8192* 
M14879 v1.13 1024 1024 64 <16 <16 1024 
NZ98/254 v1.14 256 512 <16 <16 <16 128* 
M01-240660 v1.15 4096 4096 512 <16 <16 2048 
M08-240104 v2.16 2048 128 256 >8192 2048 16 
M12566 v2.19 128 128 1024 512 256 <16 
M1239 v3.28 64 16 <16 256 2048 <16* 
M01-240988 v3.30 512 128 32 512 32 <16 
M01-240355 v3.31 256 256 128 2048 512 <16 
LNP24551 v3.116 64 64 <16 512 <16 <16 
 
